Search
Sunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalThese include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). … Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor.
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: SUTENT® CAPSULAS 25 MG, RENISUN® 25 MG CAPSULASType 2 Diabetes
go.drugbank.com/conditions/DBCOND0030616Synonyms: Type 2 Diabetes Mellitus 2, Diabete Type 2Grade 2 Oligodendroglioma
go.drugbank.com/conditions/DBCOND0168503Drugs: VorasidenibSynonyms: Grade 2 OligodendrogliomaAbemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalAbemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity … On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed
Categories: MATE 2 Inhibitors, Heterocyclic Compounds, 2-RingProducts: VERZENIO® 100 MG, VERZENIO® 150 MGApixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban was approved by the FDA on December 28, 2012[L6043].
Mixtures: ELIQUIS 30-Day Starter Pack, ELIQUIS 30-Day Starter PackCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: REVOLADE® TABLETAS 25 MG, REVOLADE ® TABLETAS 50 MGEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: XTANDI ® 40 MG, XTANDI® 40 MGRanolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.
Categories: MATE 2 Inhibitors, MATE 1 InhibitorsProducts: RANEXICOR ® 500, RANEXICOR ® 1000Pacmilimab
go.drugbank.com/drugs/DB18873InvestigationalPacmilimab is under investigation in clinical trial NCT04596150 (Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer).
Synonyms: IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH-LIGAND 1) (HUMAN MONOCLONAL CX-072 .GAMMA.4-CHAIN), DISULFIDE WITH PRODOMAIN PROTEIN (SYNTHETIC MASKING MOIETY AND CLEAVABLE MOIETY PROTEASE SUBSTRATE-CONTAINING, ) FUSION PROTEIN WITH HUMAN MONOCLONAL CDeferasirox
go.drugbank.com/drugs/DB01609ApprovedInvestigationalDeferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP1A2 InhibitorsProducts: RASIROX® 500 MG, JEDOXRED® 360 MG